5 completed, 3 withdrawn, 2 terminated, 1 unknown. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Withdrawn 3, Terminated 2, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Carcinoid Syndrome: new trials by email Literature Review of Carcinoid Syndrome trials Research Report on Carcinoid Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 36 | 2022-04-22 | 2026-03-19 |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo - Neuroendocrine Tumors, Carcinoid Syndrome | Phase 2 | Withdrawn | Chandrikha Chandrasekhara | 2021-03-03 | 2023-02-10 | |
| Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Retifanlimab, Telotristat Ethyl - Advanced Neuroendocrine Neoplasm, Carcinoid Syndrome | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-01 | 2021-09-29 | |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome | Phase 2 | Unknown | King's College Hospital NHS Trust | 20 | 2020-10-01 | 2020-08-04 |
| Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs Amino Acid Based Medical Food/Drink - Neuroendocrine Tumors, Carcinoid Tumor of GI System | Phase 2 | Completed | Lowell Anthony, MD | 10 | 2018-12-06 | 2022-11-03 |
| AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography - Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 4 | 2018-06-20 | 2025-04-10 |
| Study of Panitumumab in the Treatment of Carcinoid Syndrome Panitumumab - Carcinoid Syndrome | Phase 2 | Withdrawn | Boston Medical Center | 2013-07-01 | 2013-07-26 | |
| Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Telotristat etiprate - Carcinoid Syndrome | Phase 2 | Completed | Lexicon Pharmaceuticals | 15 | 2010-06-15 | 2019-03-15 |
| Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome BIM 23A760 - Carcinoid Syndrome | Phase 2 | Terminated | Ipsen | 8 | 2010-02-01 | 2020-11-20 |
| Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Octreotide - Carcinoid Syndrome | Phase 1 / Phase 2 | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 10 | 2009-07-01 | 2013-09-20 |
| Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Telotristat etiprate, Octreotide LAR Depot, Placebo - Carcinoid Syndrome | Phase 2 | Completed | Lexicon Pharmaceuticals | 23 | 2009-03-01 | 2018-12-26 |
Serotonin Syndrome (11) · Carcinoid Tumor (3) · Neuroendocrine Tumors (3) · Diarrhea (2) · Carcinoid Heart Disease (1) · Carcinoid Tumors, Intestinal (1)
Chemically-Induced Disorders (11) · Drug-Related Side Effects and Adverse Reactions (11) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Adenocarcinoma (3) · Carcinoma (3) · Neoplasms, Glandular and Epithelial (3) · Neuroendocrine Tumors (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Signs and Symptoms, Digestive (2) · Cardiovascular Diseases (1)
telotristat (3) · telotristat ethyl (3) · Magnetic Resonance Spectroscopy (1) · Octreotide (1) · Panitumumab (1) · Random Allocation (1) · TBR-760 (1) · alpha-methyltryptophan (1) · lutetium Lu 177 dotatate (1)
Lexicon Pharmaceuticals (2) · Barbara Ann Karmanos Cancer Institute (1) · Boston Medical Center (1) · Chandrikha Chandrasekhara (1) · Crinetics Pharmaceuticals Inc. (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Ipsen (1) · King's College Hospital NHS Trust (1) · Lowell Anthony, MD (1) · M.D. Anderson Cancer Center (1)
United States (7) · Germany (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Finland (1) · France (1) · Ireland (1) · Israel (1) · Italy (1)
Al B Benson, MD (1) · Anthony Shields (1) · Chandrikha Chandrasekharan, MD (1) · Daniel M Halperin, MD (1) · Kevan Hartshorn, MD (1) · Lowell Anthony (1) · Pablo LaPuerta, MD (1) · Pablo Lapuerta, MD (1)
PMID 25012985, PMID 25636046, PMID 27041406
2009 (2), P30CA022453 (1)